2,274
Views
36
CrossRef citations to date
0
Altmetric
Commentaries

Targeting the tumor microenvironment to improve natural killer cell-based immunotherapies: On being in the right place at the right time, with resilience

&
Pages 607-611 | Received 02 Sep 2015, Accepted 15 Sep 2015, Published online: 05 May 2016

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Shaghayegh Khanmohammadi & Nima Rezaei. (2023) CAR-NK cells: a promising cellular immunotherapy in lymphoma. Expert Opinion on Biological Therapy 23:1, pages 37-47.
Read now
Esa Jantunen, Ville Varmavuo, Jukka Pelkonen & Jaakko Valtola. (2019) Importance of early immune recovery after autologous hematopoietic cell transplantation in lymphoma patients. Leukemia & Lymphoma 60:9, pages 2115-2121.
Read now
Kejian Wang, Yue Han, William C. Cho & Huang Zhu. (2019) The rise of human stem cell-derived natural killer cells for cancer immunotherapy. Expert Opinion on Biological Therapy 19:2, pages 141-148.
Read now

Articles from other publishers (33)

Yalan Zhang, Weilin Zhou, Jiangping Yang, Jinrong Yang & Wei Wang. (2023) Chimeric antigen receptor engineered natural killer cells for cancer therapy. Experimental Hematology & Oncology 12:1.
Crossref
Fatemeh Hosseini, Mohammad Ahmadvand, Roya Karimi, Seyed Asadollah Mousavi, Jafar Ai & Mohsen Nikbakht. (2023) Cancer immunotherapy via stem cell-derived NK cells. Immunotherapy 15:12, pages 963-973.
Crossref
Amanda A. van Vliet, Ella Peters, Denise Vodegel, Daniëlle Steenmans, Monica Raimo, Susan Gibbs, Tanja D. de Gruijl, Adil D. Duru, Jan Spanholtz & Anna-Maria Georgoudaki. (2023) Early TRAIL-engagement elicits potent multimodal targeting of melanoma by CD34+ progenitor cell-derived NK cells. iScience 26:7, pages 107078.
Crossref
Mohd Farhan, Asim Rizvi, Mohammad Aatif & Aamir Ahmad. (2023) Current Understanding of Flavonoids in Cancer Therapy and Prevention. Metabolites 13:4, pages 481.
Crossref
Frederik Fabian Feigl, Anika Stahringer, Matthias Peindl, Gudrun Dandekar, Ulrike Koehl, Stephan Fricke & Dominik Schmiedel. (2023) Efficient Redirection of NK Cells by Genetic Modification with Chemokine Receptors CCR4 and CCR2B. International Journal of Molecular Sciences 24:4, pages 3129.
Crossref
Siyao Liu, Kaycee Nguyen, Dongyong Park, Nelson Wong, Anson Wang & Yubin Zhou. (2022) Harnessing natural killer cells to develop next‐generation cellular immunotherapy. Chronic Diseases and Translational Medicine 8:4, pages 245-255.
Crossref
Karol Sadowski, Wioletta Olejarz & Grzegorz Basak. (2022) Modern Advances in CARs Therapy and Creating a New Approach to Future Treatment. International Journal of Molecular Sciences 23:23, pages 15006.
Crossref
Aadhya Tiwari, Rakesh Trivedi & Shiaw-Yih Lin. (2022) Tumor microenvironment: barrier or opportunity towards effective cancer therapy. Journal of Biomedical Science 29:1.
Crossref
Liuxin Yang, Yang Yang, Yang Chen, Yuhong Xu & Jinliang Peng. (2022) Cell-based drug delivery systems and their in vivo fate. Advanced Drug Delivery Reviews 187, pages 114394.
Crossref
Sainiteesh Maddineni, John L Silberstein & John B Sunwoo. (2022) Emerging NK cell therapies for cancer and the promise of next generation engineering of iPSC-derived NK cells. Journal for ImmunoTherapy of Cancer 10:5, pages e004693.
Crossref
Muhammad Babar Khawar & Haibo Sun. (2021) CAR-NK Cells: From Natural Basis to Design for Kill. Frontiers in Immunology 12.
Crossref
Hamid Khodayari, Saeed Khodayari, Elmira Ebrahimi, Farimah Hadjilooei, Miko Vesovic, Habibollah Mahmoodzadeh, Tomo Saric, Wilfried Stücker, Stefaan Van Gool, Jürgen Hescheler & Karim Nayernia. (2021) Stem cells-derived natural killer cells for cancer immunotherapy: current protocols, feasibility, and benefits of ex vivo generated natural killer cells in treatment of advanced solid tumors. Cancer Immunology, Immunotherapy 70:12, pages 3369-3395.
Crossref
Lingtong Zhi, Xin Su, Meichen Yin, Zikang Zhang, Hui Lu, Zhiyuan Niu, Changjiang Guo, Wuling Zhu & Xuan Zhang. (2021) Genetical engineering for NK and T cell immunotherapy with CRISPR/Cas9 technology: Implications and challenges. Cellular Immunology 369, pages 104436.
Crossref
Amanda A. van Vliet, Anna-Maria Georgoudaki, Monica Raimo, Tanja D. de Gruijl & Jan Spanholtz. (2021) Adoptive NK Cell Therapy: A Promising Treatment Prospect for Metastatic Melanoma. Cancers 13:18, pages 4722.
Crossref
Hui Lu, Xiaoyan Zhao, Ziying Li, Yu Hu & Huafang Wang. (2021) From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies. Frontiers in Oncology 11.
Crossref
Xue Yao & Sandro Matosevic. (2021) Chemokine networks modulating natural killer cell trafficking to solid tumors. Cytokine & Growth Factor Reviews 59, pages 36-45.
Crossref
Hind Rafei, May Daher & Katayoun Rezvani. (2020) Chimeric antigen receptor (CAR) natural killer (NK)‐cell therapy: leveraging the power of innate immunity. British Journal of Haematology 193:2, pages 216-230.
Crossref
May Daher & Katayoun Rezvani. (2021) Outlook for New CAR-Based Therapies with a Focus on CAR NK Cells: What Lies Beyond CAR-Engineered T Cells in the Race against Cancer. Cancer Discovery 11:1, pages 45-58.
Crossref
Sandro Matosevic. (2020) Reprogramming of natural killer cells and their use in immunotherapies of solid tumors. Immunotherapy 12:9, pages 605-608.
Crossref
João Calmeiro, Mylène A. Carrascal, Adriana Ramos Tavares, Daniel Alexandre Ferreira, Célia Gomes, Amílcar Falcão, Maria Teresa Cruz & Bruno Miguel Neves. (2020) Dendritic Cell Vaccines for Cancer Immunotherapy: The Role of Human Conventional Type 1 Dendritic Cells. Pharmaceutics 12:2, pages 158.
Crossref
Huang Zhu & Dan S. Kaufman. (2019) Engineered human pluripotent stem cell-derived natural killer cells: the next frontier for cancer immunotherapy. Blood Science 1:1, pages 4-11.
Crossref
Eonju Oh, Bokyung Min, Yan Li, ChunYing Lian, JinWoo Hong, Gyeong-min Park, Bitna Yang, Sung Cho, Yu Hwang & Chae-Ok Yun. (2019) Cryopreserved Human Natural Killer Cells Exhibit Potent Antitumor Efficacy against Orthotopic Pancreatic Cancer through Efficient Tumor-Homing and Cytolytic Ability. Cancers 11:7, pages 966.
Crossref
Jennifer Ahn-Jarvis, Arti Parihar & Andrea Doseff. (2019) Dietary Flavonoids for Immunoregulation and Cancer: Food Design for Targeting Disease. Antioxidants 8:7, pages 202.
Crossref
Norimichi Hattori & Tsuyoshi Nakamaki. (2019) Natural Killer Immunotherapy for Minimal Residual Disease Eradication Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia. International Journal of Molecular Sciences 20:9, pages 2057.
Crossref
Chaopin Yang, Meng Du, Fei Yan & Zhiyi Chen. (2019) Focused Ultrasound Improves NK-92MI Cells Infiltration Into Tumors. Frontiers in Pharmacology 10.
Crossref
Kaat de Jonge, Anna Ebering, Sina Nassiri, Hélène Maby-El Hajjami, Hajer Ouertatani-Sakouhi, Petra Baumgaertner & Daniel E. Speiser. (2019) Circulating CD56bright NK cells inversely correlate with survival of melanoma patients. Scientific Reports 9:1.
Crossref
Gaurav Nayyar, Yaya Chu & Mitchell S. Cairo. (2019) Overcoming Resistance to Natural Killer Cell Based Immunotherapies for Solid Tumors. Frontiers in Oncology 9.
Crossref
Michelle L. Saetersmoen, Quirin Hammer, Bahram Valamehr, Dan S. Kaufman & Karl-Johan Malmberg. (2018) Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells. Seminars in Immunopathology 41:1, pages 59-68.
Crossref
May Daher & Katayoun Rezvani. (2018) Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering. Current Opinion in Immunology 51, pages 146-153.
Crossref
Wan-ning Wang, Guang-yu Zhou & Wen-long Zhang. (2017) NK-92 cell, another ideal carrier for chimeric antigen receptor. Immunotherapy 9:9, pages 753-765.
Crossref
Alexandra Frazao, Marina Colombo, Emmanuelle Fourmentraux-Neves, Meriem Messaoudene, Sylvie Rusakiewicz, Laurence Zitvogel, Eric Vivier, Frédéric Vély, Florence Faure, Brigitte Dréno, Houssem Benlalam, Fanny Bouquet, Ariel Savina, Eric Pasmant, Antoine Toubert, Marie-Françoise Avril & Anne Caignard. (2017) Shifting the Balance of Activating and Inhibitory Natural Killer Receptor Ligands on BRAF V600E Melanoma Lines with Vemurafenib . Cancer Immunology Research 5:7, pages 582-593.
Crossref
Meriem Messaoudene, Alexandra Frazao, Pierre Jean Gavlovsky, Antoine Toubert, Nicolas Dulphy & Anne Caignard. (2017) Patient?s Natural Killer Cells in the Era of Targeted Therapies: Role for Tumor Killers. Frontiers in Immunology 8.
Crossref
Katayoun Rezvani & Rayne H. Rouce. (2015) The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer. Frontiers in Immunology 6.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.